Barcelona-Clinic Liver Cancer (BCLC) Staging Classification

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۴

حداقل ۰ • واحد: cm

حداقل ۰

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
bclc stage
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • 0—
  • A—
  • B—
  • C—
Direct Clinical Answer

The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include performance status. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.

Clinical Indication

The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification is indicated for bedside clinical practice to support Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: BCLC is the most widely used staging system for HCC as it links stage with treatment recommendations.

Formula & Variables:

BCLC staging is determined by a combination of: 1) Performance Status (ECOG 0-4), 2) Child-Pugh class (A/B/C), 3) Tumor characteristics (size, number, portal invasion, extrahepatic spread)

Input Parameters

NameTypeRequiredDescription
performance_statusintegerYesECOG Performance Status (0=Fully active, 1=Restricted in strenuous activity, 2=Ambulatory and capable of self-care, 3=Capable of limited self-care, 4=Completely disabled)
child_pugh_classstringYesChild-Pugh classification (A=Well-preserved liver function, B=Moderate liver dysfunction, C=Severe liver damage)
tumor_sizefloatYesSize of the largest tumor in centimeters(cm)
number_of_nodulesintegerYesNumber of tumor nodules
portal_invasionstringYesPresence of portal vein invasion (macrovascular invasion)
extrahepatic_spreadstringYesPresence of extrahepatic spread (metastases)

Score Interpretation & Guidance

RangeStageDescription
—0Very Early Stage: Single nodule <2cm, PS 0, Child-Pugh A
—AEarly Stage: Single nodule or up to 3 nodules ≤3cm, PS 0, Child-Pugh A-B
—BIntermediate Stage: Multinodular, PS 0, Child-Pugh A-B
—CAdvanced Stage: Portal invasion or extrahepatic spread, PS 1-2, Child-Pugh A-B
—DTerminal Stage: Any tumor burden, PS >2 or Child-Pugh C

Evidence-Based References (EBM)

  • Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018.DOI: 10.1016/j.jhep.2021.11.018
  • Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38. doi: 10.1055/s-2007-1007122.DOI: 10.1055/s-2007-1007122
  • Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006 Apr;44(4):723-31. doi: 10.1016/j.jhep.2005.12.015.DOI: 10.1016/j.jhep.2005.12.015

Related calculators